Becton Dickinson and Co (NYSE:BDX) – Piper Jaffray Companies dropped their Q1 2020 earnings estimates for shares of Becton Dickinson and in a report released on Tuesday, November 5th. Piper Jaffray Companies analyst W. Quirk now expects that the medical instruments supplier will post earnings of $2.67 per share for the quarter, down from their previous estimate of $3.04. Piper Jaffray Companies currently has a “Overweight” rating and a $266.00 price target on the stock. Piper Jaffray Companies also issued estimates for Becton Dickinson and’s Q2 2020 earnings at $3.27 EPS, Q1 2021 earnings at $2.84 EPS, Q3 2021 earnings at $3.39 EPS, Q4 2021 earnings at $3.67 EPS and FY2021 earnings at $13.15 EPS.
Several other equities research analysts have also recently weighed in on the stock. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Morgan Stanley increased their price objective on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. Finally, Wells Fargo & Co decreased their price objective on shares of Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Wednesday. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Becton Dickinson and has a consensus rating of “Buy” and an average target price of $266.09.
BDX opened at $244.79 on Friday. Becton Dickinson and has a twelve month low of $208.62 and a twelve month high of $264.74. The company has a quick ratio of 0.67, a current ratio of 1.19 and a debt-to-equity ratio of 0.85. The company has a fifty day moving average of $251.93 and a 200-day moving average of $246.89. The stock has a market cap of $66.59 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.62 and a beta of 1.09.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.51%. The company had revenue of $4.58 billion during the quarter, compared to analysts’ expectations of $4.57 billion. During the same period in the prior year, the company posted $2.93 earnings per share. Becton Dickinson and’s revenue for the quarter was up 4.1% compared to the same quarter last year.
In related news, SVP Charles R. Bodner sold 1,514 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $260.08, for a total transaction of $393,761.12. Following the transaction, the senior vice president now directly owns 5,180 shares of the company’s stock, valued at $1,347,214.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Alexandre Conroy sold 9,829 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $255.06, for a total transaction of $2,506,984.74. Following the transaction, the executive vice president now directly owns 16,535 shares in the company, valued at $4,217,417.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,174 shares of company stock worth $8,354,013. 0.12% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Smith Shellnut Wilson LLC ADV lifted its stake in shares of Becton Dickinson and by 7.2% in the third quarter. Smith Shellnut Wilson LLC ADV now owns 1,265 shares of the medical instruments supplier’s stock valued at $320,000 after buying an additional 85 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Becton Dickinson and in the third quarter valued at $219,000. First Allied Advisory Services Inc. lifted its stake in shares of Becton Dickinson and by 1.9% in the third quarter. First Allied Advisory Services Inc. now owns 3,073 shares of the medical instruments supplier’s stock valued at $781,000 after buying an additional 58 shares in the last quarter. Cetera Advisor Networks LLC lifted its stake in shares of Becton Dickinson and by 6.4% in the third quarter. Cetera Advisor Networks LLC now owns 6,162 shares of the medical instruments supplier’s stock valued at $1,563,000 after buying an additional 371 shares in the last quarter. Finally, Miracle Mile Advisors LLC lifted its stake in shares of Becton Dickinson and by 7.0% in the third quarter. Miracle Mile Advisors LLC now owns 1,431 shares of the medical instruments supplier’s stock valued at $362,000 after buying an additional 93 shares in the last quarter. 84.29% of the stock is currently owned by institutional investors and hedge funds.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: How to invest in a bear market
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.